Featured Article

Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After · stunning trends

Heather Aug 05, 2026

Figure 1 from Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Figure 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After

FIGURE 1 : Change in HbA1c from the start of study drug administration to week 52 - " Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study"

Glucose dependent insulinotropic polypeptide GIP secretion
Glucose dependent insulinotropic polypeptide GIP secretion

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.

Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

The Road towards Triple Agonists Glucagon Like Peptide 1 Glucose
The Road towards Triple Agonists Glucagon Like Peptide 1 Glucose

Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c , both on a ...

To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.

Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After
Table 1 from Effect on Hemoglobin A1c HbA1c and Body Weight After

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.

The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.

Glucose dependent Insulinotropic Polypeptide GIP Phoenix
Glucose dependent Insulinotropic Polypeptide GIP Phoenix

Overview of Figure 1 From Effect On Hemoglobin A1C Hba1C And Body Weight After

Introduction To evaluate real-world hemoglobin A1c ( HbA1c ) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. Methods This retrospective analysis utilized the Healthcare Integrated ...

This post hoc analysis assessed the HbA1c -lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4-6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular ...

Figure 1 from Glucose Dependent Insulinotropic Polypeptide Stimulation
Figure 1 from Glucose Dependent Insulinotropic Polypeptide Stimulation

Key Details About Figure 1 From Effect On Hemoglobin A1C Hba1C And Body Weight After

TZP was more efficacious than placebo or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline.

Glucose dependent insulinotropic polypeptide receptor GIPR gene
Glucose dependent insulinotropic polypeptide receptor GIPR gene
dependent insulinotropic polypeptide hba1c
dependent insulinotropic polypeptide hba1c
Glucagon like Peptide 1 Glucose Dependent Insulinotropic Polypeptide
Glucagon like Peptide 1 Glucose Dependent Insulinotropic Polypeptide
Improving Physicochemical Properties of Biopharmaceutical Drug
Improving Physicochemical Properties of Biopharmaceutical Drug

Figure 3 shows changes in HbA1c over the course of the trial and two years after drug discontinuation. Two months after discontinuing tirzepatide, re-elevation of HbA1c was observed ( Figure 3). ...